Estimated log-hazard ratio (standard error) for the effect of previous events on future events*. Table 9 Description and results for sensitivity analyses conducted.
Sensitivity analysis Description Results

Reduced cohort age
The initial age of the cohort was changed from 70 (mean in RCTs) to 60. This increased state utilities but other parameters were independent of age.
Apixaban 5mg still had highest probability of greatest net benefit (approximately 60%). Increased cohort age Initial age of cohort changed from 70 (mean in RCTs) to 80. This decreased state utilities but other parameters were independent of age.
Apixaban 5mg still had highest probability of greatest net benefit (approximately 60%).
No warfarin cost
Warfarin drug and administration costs were set to zero. Apixaban 5mg still had highest probability of greatest net benefit (approximately 60%). No ICH or bleed effect on mortality risk Assumed ICH and bleed had no effect on future mortality, whereas the base case assumed the same effect as a history of stroke.
Reduced treatment switching Assumed patients only switched to no treatment following an ICH or MI (if on dabigatran).
Increased treatment switching
Assumed patients always switched after stroke, bleed, ICH, MI (if on dabigatran), TIA or SE.
Warfarin had highest probability of greatest net benefit (above 80%). Removed BAATAF study Removed the BAATAF study, in which control patients could receive aspirin, from the meta-analysis comparing warfarin to no treatment Apixaban 5mg still had highest probability of greatest net benefit (approximately 60%). Lower Apixaban and dabigatran dose Assumed lower doses of apixaban 2.5mg and dabigatran 110mg using efficacy and safety rates estimated in the NMA [6] , as these are recommended in older patients. Apixaban 2.5mg had highest probability of greatest net benefit but probability was closer to 30% and other DOACs had probability of between 20% and 30%. No warfarin effect on ICH Assumed the hazard ratio of ICH on warfarin relative to no treatment was 1. The base case assumed it was the same as that for bleed (0.51 (0.205, 0.949)) .
MI management cost
Changed post-MI cost to £142 Apixaban 5mg still had highest probability of greatest net benefit (approximately 60%).
Price threshold analysis Calculated price at which warfarin, dabigatran, edoxaban, and rivaroxaban would have to be sold to become most cost-effective (Assuming all other drug prices remain fixed)
Found warfarin, dabigatran, edoxaban, and rivaroxaban would have to be sold at annual prices of -£1393.79, £487.86, £222.93, and £201.47, respectively, to have a greater expected net benefit than apixaban. The 10-year horizon population EVPI increases from £17.9 million to £48.5 million, £32.6 million, £33.5 million, and £37.9 million for the coumarin, dabigatran, edoxaban, and rivaroxaban threshold prices, respectively. DOAC monitoring cost Assumed monitoring costs for DOACs to be 50% of those for warfarin. Apixaban 5mg had highest probability of greatest net benefit, approximately 60% Normal cost and utility distributions Used Normal distributions for all utility and cost parameters that followed uniform distributions in the base case. Standard deviations of normal selected so that 95% range matched upper and lower limits of the uniforms.
Apixaban 5mg remained most costeffective with probability approximately 60%. The EVPI also remained unchanged. Prior stroke Assuming all patients begin with a history of stoke. Apixaban still has highest expected net benefit and probability of greatest net benefit (39.5%) but it is followed by warfarin (22.3%), then dabigatran (19.7%) and edoxaban (17.5%). No treatment switch after MI on dabigatran Assuming patients do not switch to warfarin following MI on dabigatran (base case assumed all patients switched from dabigatran following MI, but not on other DOACs) Apixaban 5mg still had highest probability of greatest net benefit (58%). 
